MovDisordV3, PascalFrancis, Corpus, bibRecord, 001359

Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial

Identifieur interne : 001359 ( PascalFrancis/Corpus ); précédent : 001358; suivant : 001360

Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial

Auteurs : Carmine Vitale ; Stefano Marconi ; Luigi Di Maio ; Giuseppe De Michele ; Katia Longo ; Vincenzo Bonavita ; Paolo Barone

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:08-0147464

Descripteurs français

Pascal (Inist)
- Syndrome choréique, Chorée de Huntington, Pathologie du système nerveux, Court terme, Apomorphine, Traitement.

English descriptors

KwdEn :
- Chorea, Huntington disease, Nervous system diseases, Short term, Treatment.

Abstract

We evaluated tolerability and the efficacy of continuous infusion of apomorphine hydrochloride on involuntary movements and mood disorder in Huntington's disease (HD) patients in a pilot, single center, double-blind, randomized, crossover, and controlled versus placebo study. Nine patients with a molecular diagnosis of HD were screened for response to acute apomorphine injection. Four of them, not ameliorating at the acute test, were discontinued. Five patients, responding to acute apomorphine, received continuous infusion of either apomorphine or placebo for 5 days. After 2 days of washout, the alternative treatment was administered. Primary endpoint measures were scores of the Unified Huntington's Disease Rating Scale (UHDRS "motor section") and of the Abnormal Involuntary Movement Scale (AIMS). Secondary endpoint measures were the Hamilton Depression Rating Scale (HAD) score and safety parameters. Both UHDRS and AIMS scores significantly decreased in all patients after apomorphine. The beneficial effect of apomorphine was recorded throughout the 5 treatment days. The HAD score did not change after infusion of either treatment. No serious adverse events were reported by either group during the study. Our results suggest that continuous infusion of apomorphine might be considered for the treatment of involuntary movements in some HD patients.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 22`
A06				`@2 16`
A08	`01`	`1`	`ENG`	`@1 Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial`
A11	`01`	`1`		`@1 VITALE (Carmine)`
A11	`02`	`1`		`@1 MARCONI (Stefano)`
A11	`03`	`1`		`@1 DI MAIO (Luigi)`
A11	`04`	`1`		`@1 DE MICHELE (Giuseppe)`
A11	`05`	`1`		`@1 LONGO (Katia)`
A11	`06`	`1`		`@1 BONAVITA (Vincenzo)`
A11	`07`	`1`		`@1 BARONE (Paolo)`
A14	`01`			`@1 Department of Neurological Sciences, University "Federico II," @2 Naples @3 ITA @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A14	`02`			`@1 Istituto di Diagnostica e Cura "Hermitage Capodimonte," @2 Naples @3 ITA @Z 1 aut. @Z 6 aut.`
A14	`03`			`@1 Medical Department, Chiesi Farmaceutici S.p.A @2 Parma @3 ITA @Z 2 aut.`
A20				`@1 2359-2364`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000162715700090`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 34 ref.`
A47	`01`	`1`		`@0 08-0147464`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We evaluated tolerability and the efficacy of continuous infusion of apomorphine hydrochloride on involuntary movements and mood disorder in Huntington's disease (HD) patients in a pilot, single center, double-blind, randomized, crossover, and controlled versus placebo study. Nine patients with a molecular diagnosis of HD were screened for response to acute apomorphine injection. Four of them, not ameliorating at the acute test, were discontinued. Five patients, responding to acute apomorphine, received continuous infusion of either apomorphine or placebo for 5 days. After 2 days of washout, the alternative treatment was administered. Primary endpoint measures were scores of the Unified Huntington's Disease Rating Scale (UHDRS "motor section") and of the Abnormal Involuntary Movement Scale (AIMS). Secondary endpoint measures were the Hamilton Depression Rating Scale (HAD) score and safety parameters. Both UHDRS and AIMS scores significantly decreased in all patients after apomorphine. The beneficial effect of apomorphine was recorded throughout the 5 treatment days. The HAD score did not change after infusion of either treatment. No serious adverse events were reported by either group during the study. Our results suggest that continuous infusion of apomorphine might be considered for the treatment of involuntary movements in some HD patients.
C02	`01`	`X`		`@0 002B17`
C03	`01`	`X`	`FRE`	`@0 Syndrome choréique @5 01`
C03	`01`	`X`	`ENG`	`@0 Chorea @5 01`
C03	`01`	`X`	`SPA`	`@0 Corea síndrome @5 01`
C03	`02`	`X`	`FRE`	`@0 Chorée de Huntington @5 02`
C03	`02`	`X`	`ENG`	`@0 Huntington disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Corea Huntington @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Court terme @5 09`
C03	`04`	`X`	`ENG`	`@0 Short term @5 09`
C03	`04`	`X`	`SPA`	`@0 Corto plazo @5 09`
C03	`05`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR @5 10`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 11`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 11`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 11`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Mouvement involontaire @5 39`
C07	`03`	`X`	`ENG`	`@0 Involuntary movement @5 39`
C07	`03`	`X`	`SPA`	`@0 Movimiento involuntario @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Trouble neurologique @5 42`
C07	`05`	`X`	`ENG`	`@0 Neurological disorder @5 42`
C07	`05`	`X`	`SPA`	`@0 Trastorno neurológico @5 42`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 43`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 43`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 43`
C07	`07`	`X`	`FRE`	`@0 Maladie héréditaire @5 44`
C07	`07`	`X`	`ENG`	`@0 Genetic disease @5 44`
C07	`07`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 44`
N21				`@1 091`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0147464 INIST
ET :	Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial
AU :	VITALE (Carmine); MARCONI (Stefano); DI MAIO (Luigi); DE MICHELE (Giuseppe); LONGO (Katia); BONAVITA (Vincenzo); BARONE (Paolo)
AF :	Department of Neurological Sciences, University "Federico II,"/Naples/Italie (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.); Istituto di Diagnostica e Cura "Hermitage Capodimonte,"/Naples/Italie (1 aut., 6 aut.); Medical Department, Chiesi Farmaceutici S.p.A/Parma/Italie (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 16; Pp. 2359-2364; Bibl. 34 ref.
LA :	Anglais
EA :	We evaluated tolerability and the efficacy of continuous infusion of apomorphine hydrochloride on involuntary movements and mood disorder in Huntington's disease (HD) patients in a pilot, single center, double-blind, randomized, crossover, and controlled versus placebo study. Nine patients with a molecular diagnosis of HD were screened for response to acute apomorphine injection. Four of them, not ameliorating at the acute test, were discontinued. Five patients, responding to acute apomorphine, received continuous infusion of either apomorphine or placebo for 5 days. After 2 days of washout, the alternative treatment was administered. Primary endpoint measures were scores of the Unified Huntington's Disease Rating Scale (UHDRS "motor section") and of the Abnormal Involuntary Movement Scale (AIMS). Secondary endpoint measures were the Hamilton Depression Rating Scale (HAD) score and safety parameters. Both UHDRS and AIMS scores significantly decreased in all patients after apomorphine. The beneficial effect of apomorphine was recorded throughout the 5 treatment days. The HAD score did not change after infusion of either treatment. No serious adverse events were reported by either group during the study. Our results suggest that continuous infusion of apomorphine might be considered for the treatment of involuntary movements in some HD patients.
CC :	002B17
FD :	Syndrome choréique; Chorée de Huntington; Pathologie du système nerveux; Court terme; Apomorphine; Traitement
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Mouvement involontaire; Pathologie du système nerveux central; Trouble neurologique; Maladie dégénérative; Maladie héréditaire
ED :	Chorea; Huntington disease; Nervous system diseases; Short term; Treatment
EG :	Cerebral disorder; Extrapyramidal syndrome; Involuntary movement; Central nervous system disease; Neurological disorder; Degenerative disease; Genetic disease
SD :	Corea síndrome; Corea Huntington; Sistema nervioso patología; Corto plazo; Tratamiento
LO :	INIST-20953.354000162715700090
ID :	08-0147464

Links to Exploration step

Pascal:08-0147464

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial</title>
<author><name sortKey="Vitale, Carmine" sort="Vitale, Carmine" uniqKey="Vitale C" first="Carmine" last="Vitale">Carmine Vitale</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Istituto di Diagnostica e Cura "Hermitage Capodimonte,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marconi, Stefano" sort="Marconi, Stefano" uniqKey="Marconi S" first="Stefano" last="Marconi">Stefano Marconi</name>
<affiliation><inist:fA14 i1="03"><s1>Medical Department, Chiesi Farmaceutici S.p.A</s1>
<s2>Parma</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Di Maio, Luigi" sort="Di Maio, Luigi" uniqKey="Di Maio L" first="Luigi" last="Di Maio">Luigi Di Maio</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Michele, Giuseppe" sort="De Michele, Giuseppe" uniqKey="De Michele G" first="Giuseppe" last="De Michele">Giuseppe De Michele</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Longo, Katia" sort="Longo, Katia" uniqKey="Longo K" first="Katia" last="Longo">Katia Longo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonavita, Vincenzo" sort="Bonavita, Vincenzo" uniqKey="Bonavita V" first="Vincenzo" last="Bonavita">Vincenzo Bonavita</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Istituto di Diagnostica e Cura "Hermitage Capodimonte,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0147464</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0147464 INIST</idno>
<idno type="RBID">Pascal:08-0147464</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001359</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial</title>
<author><name sortKey="Vitale, Carmine" sort="Vitale, Carmine" uniqKey="Vitale C" first="Carmine" last="Vitale">Carmine Vitale</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Istituto di Diagnostica e Cura "Hermitage Capodimonte,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marconi, Stefano" sort="Marconi, Stefano" uniqKey="Marconi S" first="Stefano" last="Marconi">Stefano Marconi</name>
<affiliation><inist:fA14 i1="03"><s1>Medical Department, Chiesi Farmaceutici S.p.A</s1>
<s2>Parma</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Di Maio, Luigi" sort="Di Maio, Luigi" uniqKey="Di Maio L" first="Luigi" last="Di Maio">Luigi Di Maio</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Michele, Giuseppe" sort="De Michele, Giuseppe" uniqKey="De Michele G" first="Giuseppe" last="De Michele">Giuseppe De Michele</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Longo, Katia" sort="Longo, Katia" uniqKey="Longo K" first="Katia" last="Longo">Katia Longo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonavita, Vincenzo" sort="Bonavita, Vincenzo" uniqKey="Bonavita V" first="Vincenzo" last="Bonavita">Vincenzo Bonavita</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Istituto di Diagnostica e Cura "Hermitage Capodimonte,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chorea</term>
<term>Huntington disease</term>
<term>Nervous system diseases</term>
<term>Short term</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome choréique</term>
<term>Chorée de Huntington</term>
<term>Pathologie du   système nerveux</term>
<term>Court terme</term>
<term>Apomorphine</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We evaluated tolerability and the efficacy of continuous infusion of apomorphine hydrochloride on involuntary movements and mood disorder in Huntington's disease (HD) patients in a pilot, single center, double-blind, randomized, crossover, and controlled versus placebo study. Nine patients with a molecular diagnosis of HD were screened for response to acute apomorphine injection. Four of them, not ameliorating at the acute test, were discontinued. Five patients, responding to acute apomorphine, received continuous infusion of either apomorphine or placebo for 5 days. After 2 days of washout, the alternative treatment was administered. Primary endpoint measures were scores of the Unified Huntington's Disease Rating Scale (UHDRS "motor section") and of the Abnormal Involuntary Movement Scale (AIMS). Secondary endpoint measures were the Hamilton Depression Rating Scale (HAD) score and safety parameters. Both UHDRS and AIMS scores significantly decreased in all patients after apomorphine. The beneficial effect of apomorphine was recorded throughout the 5 treatment days. The HAD score did not change after infusion of either treatment. No serious adverse events were reported by either group during the study. Our results suggest that continuous infusion of apomorphine might be considered for the treatment of involuntary movements in some HD patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>16</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VITALE (Carmine)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MARCONI (Stefano)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DI MAIO (Luigi)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DE MICHELE (Giuseppe)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LONGO (Katia)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BONAVITA (Vincenzo)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BARONE (Paolo)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurological Sciences, University "Federico II,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Istituto di Diagnostica e Cura "Hermitage Capodimonte,"</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Medical Department, Chiesi Farmaceutici S.p.A</s1>
<s2>Parma</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>2359-2364</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000162715700090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>34 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0147464</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We evaluated tolerability and the efficacy of continuous infusion of apomorphine hydrochloride on involuntary movements and mood disorder in Huntington's disease (HD) patients in a pilot, single center, double-blind, randomized, crossover, and controlled versus placebo study. Nine patients with a molecular diagnosis of HD were screened for response to acute apomorphine injection. Four of them, not ameliorating at the acute test, were discontinued. Five patients, responding to acute apomorphine, received continuous infusion of either apomorphine or placebo for 5 days. After 2 days of washout, the alternative treatment was administered. Primary endpoint measures were scores of the Unified Huntington's Disease Rating Scale (UHDRS "motor section") and of the Abnormal Involuntary Movement Scale (AIMS). Secondary endpoint measures were the Hamilton Depression Rating Scale (HAD) score and safety parameters. Both UHDRS and AIMS scores significantly decreased in all patients after apomorphine. The beneficial effect of apomorphine was recorded throughout the 5 treatment days. The HAD score did not change after infusion of either treatment. No serious adverse events were reported by either group during the study. Our results suggest that continuous infusion of apomorphine might be considered for the treatment of involuntary movements in some HD patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome choréique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Chorea</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Corea síndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Chorée de Huntington</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Huntington disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Corea Huntington</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Court terme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Short term</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Corto plazo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>44</s5>
</fC07>
<fN21><s1>091</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0147464 INIST</NO>
<ET>Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial</ET>
<AU>VITALE (Carmine); MARCONI (Stefano); DI MAIO (Luigi); DE MICHELE (Giuseppe); LONGO (Katia); BONAVITA (Vincenzo); BARONE (Paolo)</AU>
<AF>Department of Neurological Sciences, University "Federico II,"/Naples/Italie (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.); Istituto di Diagnostica e Cura "Hermitage Capodimonte,"/Naples/Italie (1 aut., 6 aut.); Medical Department, Chiesi Farmaceutici S.p.A/Parma/Italie (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 16; Pp. 2359-2364; Bibl. 34 ref.</SO>
<LA>Anglais</LA>
<EA>We evaluated tolerability and the efficacy of continuous infusion of apomorphine hydrochloride on involuntary movements and mood disorder in Huntington's disease (HD) patients in a pilot, single center, double-blind, randomized, crossover, and controlled versus placebo study. Nine patients with a molecular diagnosis of HD were screened for response to acute apomorphine injection. Four of them, not ameliorating at the acute test, were discontinued. Five patients, responding to acute apomorphine, received continuous infusion of either apomorphine or placebo for 5 days. After 2 days of washout, the alternative treatment was administered. Primary endpoint measures were scores of the Unified Huntington's Disease Rating Scale (UHDRS "motor section") and of the Abnormal Involuntary Movement Scale (AIMS). Secondary endpoint measures were the Hamilton Depression Rating Scale (HAD) score and safety parameters. Both UHDRS and AIMS scores significantly decreased in all patients after apomorphine. The beneficial effect of apomorphine was recorded throughout the 5 treatment days. The HAD score did not change after infusion of either treatment. No serious adverse events were reported by either group during the study. Our results suggest that continuous infusion of apomorphine might be considered for the treatment of involuntary movements in some HD patients.</EA>
<CC>002B17</CC>
<FD>Syndrome choréique; Chorée de Huntington; Pathologie du système nerveux; Court terme; Apomorphine; Traitement</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Mouvement involontaire; Pathologie du   système nerveux central; Trouble neurologique; Maladie dégénérative; Maladie héréditaire</FG>
<ED>Chorea; Huntington disease; Nervous system diseases; Short term; Treatment</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Involuntary movement; Central nervous system disease; Neurological disorder; Degenerative disease; Genetic disease</EG>
<SD>Corea síndrome; Corea Huntington; Sistema nervioso patología; Corto plazo; Tratamiento</SD>
<LO>INIST-20953.354000162715700090</LO>
<ID>08-0147464</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001359 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001359 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0147464
   |texte=   Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial

Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri